Preliminary Results of the Sunlight OmnisenseTM Bone Sonometer: In-vivo and In-vitro Precision and Correlation with DXA.
Quantitative ultrasound systems to date have concentrated on single site measurements using transmission mode ultrasound. A new type of quantitative ultrasound system, the OmnisenseTM, has been developed (Sunlight Ltd) which is capable of measurements at multiple sites using shortest propagation time ultrasound technology and a hand held probe. This has enabled measurements of sites previously inaccessible using ultrasound. A preliminary evaluation of the recently upgraded Omnisense was made, assessing the in-vivo and in-vitro precision and the correlation of the distal radius and the mid shaft tibia with dual x-ray absorptiometry (DXA) measurements of the lumbar spine, neck of femur and total hip. The in-vitro precision was assessed by performing daily scans on a perspex phantom. A group of 20 subjects (8 male, 12 female, age 23-55, BMI 17-40) were measured 5 times each on the same day. Measurements were taken at the distal radius and mid shaft tibia with repositioning between measurements to evaluate the intra-operator in-vivo short term precision. Finally, a group of 40 subjects of varying osteoporotic status were measured on both the Omnisense and DXA. After correction for temperature variation the in-vitro CV was 0.03%. The in-vivo root mean square CV for the distal radius was 0.54% and the mid shaft tibia 0.58%. The correlation’s between the Omnisense speed of sound (SOS) measurements and DXA bone mineral density (BMD) are shown in the table.
In conclusion, the in-vitro precision demonstrates an extremely stable system, with the in-vivo short-term precision results also showing good precision. Only weak to fair correlation’s with DXA were found. This may be explained by the fact that SOS is a function of both the density and the elasticity of bone.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More